The company J. Craig Venter founded in 1998 to challenge the Human Genome Project ran a data center with 70 terabytes of storage. Venter's latest scheme--creating the world's largest sequencing center--will fill that in less than one week.
Noninvasive prenatal blood tests are making a market splash--and Illumina's diagnostic might surpass the competition: A new study found that the company's innovative test for Down syndrome and other genetic abnormalities outperforms current screening methods, and reduces false-positive results when compared with traditional testing.
In 2013, at least four companies debuted new, cutting-edge prenatal blood tests for Down syndrome and other genetic abnormalities. One--Illumina--takes a step ahead of the pack with a new study that shows its offering drastically slashes the false-positive rate for fetal chromosomal abnormalities versus current test standards.
As the cost of sequencing a whole human genome has edged downward toward the fabled $1,000 mark, some observers have become increasingly concerned about how much time and money it will take to analyze the data. To clear the potential bottleneck, U.S. researchers have applied a supercomputer to the task.
Illumina is throwing its cachet and its $1,000 genome sequencing system behind a San Francisco genomics startup incubator backed by Russian billionaire Yuri Milner.
Tech startup incubator Y Combinator has a reputation as a spawning ground for major companies, with Dropbox and Airbnb among those passing through its program. Yuri Milner played a role in the accelerator in recent years, but reduced his commitment in December. Now, he has revealed that some of the cash and time this freed up will go into running a genomics incubator with Illumina.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug...
Illumina is a company that has become used to success. Yet this week a collaboration between Illumina and The Scripps Research Institute lost to a Stanford University-led academic consortium in a bid for a $40 million grant to set up a stem cell genomics center in California.
This month, Illumina announced it had achieved the elusive $1,000 genome. Critics have quibbled with their math--and now entrepreneurially minded researchers in Japan are readying an "ultra-low cost" genome sequencing system for the market next year.
Illumina boosted its revenue 24% last year thanks to an expanded share of the gene-sequencing market and a deeper dive into diagnostics, and now, thanks in part to the launch of $1,000 genome technology, the company has big expectations for 2014.